We read with great interest the recent phase II studies by Levy et al. and Hirschfield et al., which evaluated elafibranor and bexotegrast, respectively, for the treatment of primary sclerosing cholangitis (PSC).1,2 The ELMWOOD trial demonstrated dose-dependent biochemical improvements of alkaline phosphatase (ALP) levels at 12 weeks, with least-squares mean relative reductions vs placebo of 35% and 55% with elafibranor 80 mg and 120 mg, respectively; notably, ALP normalization was observed only in participants receiving elafibranor (80 mg: 9%, 120 mg: 17%).
Journal of Hepatology published a clinical update in Research Highlights on 17 Mar 2026.
The item focuses on Beyond alkaline phopshatase: can anti–integrin αvβ6 autoantibodies serve as biomarkers in primary sclerosing cholangitis trials?.
Review the original article for the full source wording and details.